Teva Pharmaceutical Industries (NYSE:TEVA) is back in focus after its first quarter 2026 report, where sales, earnings and impairment charges all shifted, and management kept full year revenue guidance unchanged.

The strong first quarter and renewed focus on branded biopharma have come alongside a 21.86% 1 month share price return and a very large 3 year total shareholder return. This suggests that momentum has been building over both shorter and longer horizons.

If Teva’s recent run has you looking beyond a single healthcare stock, it may be a good time to widen the search and check out 32 healthcare AI stocks

With Teva shares up 21.9% over the past month and the stock trading about 11% below the average analyst price target and roughly 37% below an intrinsic value estimate, is there still a buying opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 9.4% Undervalued

Teva’s most followed valuation narrative puts fair value at $40.09 per share versus the last close at $36.34, framing a modest discount that rests on detailed assumptions about growth, margins, and future valuation multiples.

The accelerating launch cadence of biosimilars (with 8 launches targeted through 2027 and a goal to double biosimilar revenue), backed by favorable regulatory trends increasing biosimilar adoption in major markets, should unlock incremental, higher-margin revenue streams and offset headwinds from traditional generics, powering long-term EBITDA growth.

Want to see what sits behind that growth story and valuation gap? The narrative leans on measured revenue expansion, improving margins, and a richer earnings multiple. Curious how those pieces fit together into a $40.09 fair value call?

Result: Fair Value of $40.09 (UNDERVALUED)

However, that story can quickly look different if Teva’s heavy debt load restricts R&D and biosimilar execution stumbles, challenging the earnings and P/E assumptions behind $40.09.

Another View: Multiples Point To A Richer Price Tag

So far, the narratives and fair value estimates point to Teva trading at a discount, but the market’s own pricing sends a different signal. At a P/E of 27x versus a fair ratio of 21.6x, Teva looks expensive, and it also trades above the US Pharmaceuticals average of 16.7x and a peer average of 20.2x. That gap suggests less room for error if the growth and margin story falls short, so how comfortable are you with paying a premium today?

Next Steps

With mixed signals on value and expectations, the real question is what you make of the story. Act while the data is fresh by weighing both the risks and potential upside using the 3 key rewards and 2 important warning signs

Looking for more investment ideas?

Do not stop at a single stock when there are other opportunities worth sizing up. Use these focused tools now so you do not miss something compelling.

• Target income potential by checking out companies in the 12 dividend fortresses that might suit a portfolio built around regular cash flows.
• Hunt for quality at a discount with the screener containing 23 high quality undiscovered gems that highlight stocks many investors may be overlooking today.
• Prioritise resilience by scanning the 74 resilient stocks with low risk scores to see stocks that score well on stability and lower overall risk.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.